Medincell
Medincell, a pioneering biopharmaceutical company headquartered in France, focuses on the development of innovative long-acting injectable therapies. Founded in 2000, the company has made significant strides in the industry, particularly in the fields of mental health and chronic diseases. Medincell's proprietary technology platform, which enables the sustained release of active pharmaceutical ingredients, sets it apart from competitors. With a strong presence in Europe and expanding operations globally, Medincell is committed to addressing unmet medical needs through its core products, including its lead candidate for the treatment of schizophrenia. The company has garnered recognition for its unique approach to drug delivery, positioning itself as a leader in the biopharmaceutical sector. Medincell continues to advance its mission of improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Medincell's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medincell's score of 44 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medincell's reported carbon emissions
In 2023, Medincell reported total carbon emissions of approximately 5,194,776 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 776 kg CO2e, while Scope 2 emissions accounted for approximately 40,820 kg CO2e. The majority of their emissions, approximately 5,153,180 kg CO2e, fell under Scope 3, which includes significant contributions from purchased goods and services (about 5,120,280 kg CO2e) and business travel (approximately 253,000 kg CO2e). Over the years, Medincell has shown a notable increase in total emissions, rising from about 96,300 kg CO2e in 2020 to approximately 6,660,740 kg CO2e in 2022. Despite this increase, there are currently no publicly disclosed reduction targets or climate pledges from the company, indicating a potential area for future commitment to sustainability and emissions reduction initiatives. Overall, Medincell's emissions profile highlights the importance of addressing Scope 3 emissions, which represent the largest portion of their carbon footprint, as they continue to navigate their climate commitments in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 000 |
| Scope 2 | 7,640 | 0,000 | 0,000 | 00,000 | 00,000 |
| Scope 3 | - | 00,000 | 000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medincell is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
